We are live on ! Find out more
BIAF icon

bioAffinity Technologies

16 hedge funds and large institutions have $133K invested in bioAffinity Technologies in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more funds holding

Funds holding: 15 → 16 (+1)

0.15% less ownership

Funds ownership: 3.45% → 3.3% (-0.15%)

29% less capital inflows, than outflows

Capital inflows: $57.5K | Capital outflows: $81.1K

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BIAF Hedge Fund Activity: Q1 2025 in Review

16 of the 7,491 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q1 2025, worth a combined $133K — down 73% from $499K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BIAF positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.

The largest buyer was Warberg Asset Management, opening a new position worth an estimated $13.7K. The largest seller was Vanguard Group, cutting an estimated $51.4K.

  • 16 institutional investors held bioAffinity Technologies (BIAF) as of Q1 2025, up from 15 in Q4 2024.
  • Funds reported $133K of bioAffinity Technologies stock for Q1 2025, down 73% quarter-over-quarter.
  • 4 funds opened new bioAffinity Technologies positions in Q1 2025 and 3 closed out, a net change of +1 holder.
  • The largest bioAffinity Technologies buyer in Q1 2025 was Warberg Asset Management, an estimated $13.7K added.
  • The largest bioAffinity Technologies seller in Q1 2025 was Vanguard Group, an estimated $51.4K sold.

Based on aggregated 13F filings for Q1 2025.